Our Commitment to Improving Lives Through Access

Paying for treatment shouldn’t get in the way of your patient’s health. That’s why the Horizon By Your Side team is diligent in exploring all options to help your patient.

Does your patient have commercial insurance, like a preferred provider organization (PPO) or health maintenance organization (HMO)? If so, they may qualify for a lower co-pay*
Does your patient have government insurance, such as Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, Department of Defense, TRICARE, or any state, patient foundation, or other pharmaceutical program? If so, there may be additional support for them
Once your treatment plan is set in place, the Patient Access Liaison can help talk with your patient about the insurance approval process and what the potential out-of-pocket treatment costs may be

Through our team’s knowledge of how insurance companies work and our understanding of your specific benefits, the Patient Access Liaison can help your patient understand the insurance process by walking them through coverage and possible financial assistance options.

Shared Responsibility

As an industry partner, we have limitations that we must respect. We cannot guarantee access or reimbursement for our medicines; however, we can educate you and your staff about gaining access to the medicine and various patient financial support programs. Similarly, we cannot provide medical advice to your patient about the medicines you prescribe or act as an extension of—or substitution for—your staff.

Together, we can advocate for your patient to gain access to the medicines you believe will improve their lives.

Independent Organizations That Can Provide Foundational Assistance for Your Patient

The Assistance Fund

The Assistance Fund is an independent charitable patient assistance organization that provides support for adults and children with rare and chronic diseases. The organization may help provide families with financial and travel assistance.

https://TAFcares.org/

Good Days

Good Days works to improve the health and quality of life of patients with chronic disease, cancer, or other life-altering conditions. The organization may help provide families with financial and travel assistance.

https://MyGoodDays.org/

National Organization for Rare Disorders (NORD)

NORD is a patient advocacy organization dedicated to people with rare diseases and the groups that help them. NORD provides patients and families with advocacy information, assistance programs, and connections to patient organizations.

NORD also has an Emergency Relief Program. This fund provides financial assistance that can be used
to pay for unexpected or emergency non-medical expenses such as utility expenses, cellular or internet service, emergency repairs to car, home or major appliance, and rent or mortgage payment assistance.

https://rarediseases.org

Find out how you can initiate enrollment for your patient

*The Horizon Commercial Co-Pay Program may be available to patients who meet the following minimum criteria:

Patient’s prescription cannot be paid in part or in full by any government-funded program including but not limited to: Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, Department of Defense (DOD), TRICARE, or any state, patient foundation, or other pharmaceutical program
Patient is prescribed a covered Horizon rare disease medication for an indication approved by the Food and Drug Administration; the indication for each product is shown in its prescribing information
Patient is a resident of the United States
Patient must be commercially insured and have financial responsibility for a portion of the drug and/or infusion cost if applicable

The assistance offered under this co-pay program is subject to additional terms and conditions, including but not limited to the following:

Terms and Conditions: Offer cannot be combined with any other rebate or coupon, free trial, or similar offer for the specified prescription. Not valid for prescriptions reimbursed in whole or in part by any government-funded program including but not limited to Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE, or any state, patient foundation, or other pharmaceutical program. Offer good only in the United States at participating specialty pharmacies or sites of care. Offer not valid where otherwise prohibited by law, for example by applicable state law prohibiting co-pay cards. Horizon reserves the right to rescind, revoke, or amend offer without notice. The selling, purchasing, trading, or counterfeiting of any co-pay card or benefits is prohibited by law. This co-pay program is not insurance and is not intended to substitute for insurance. Age for eligibility is dependent on product indication.

Participating Pharmacies or Healthcare Providers: By using this co-pay program, you acknowledge and confirm that the prescription will not be reimbursed in whole or in part by any government-funded program (such as, without limitation, Medicare, Medicaid, VA, DOD, TRICARE) and the patient and prescription meet the eligibility criteria set forth in the terms and conditions. You are responsible for reporting the receipt of the co-pay program benefits as required by an insurer, payor, or applicable law or regulation.

Patients: By enrolling in this co-pay program, you acknowledge and confirm that you and the prescription meet the eligibility requirements set forth in the terms and conditions, including that the prescription will not be reimbursed in whole or in part by any government-funded program (such as, without limitation, Medicare, Medicaid, VA, DOD, TRICARE). You may not seek any claims to government payors or other payors or insurers for this prescription. You may not seek reimbursement from any health savings, flexible savings, or other healthcare reimbursement account for any amounts received from the co-pay program. You are responsible for reporting the receipt of the co-pay program benefits as required by an insurer, payor, or applicable law or regulation.

INDICATION and IMPORTANT SAFETY INFORMATION

INDICATION

BUPHENYL (sodium phenylbutyrate) Tablets for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration are indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).

BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy.

BUPHENYL must be used with dietary protein restriction and, in some cases, essential amino acid supplementation.

Any episode of acute hyperammonemia should be treated as a life-threatening emergency.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Acute hyperammonemia: BUPHENYL should not be used to manage acute hyperammonemia, which is a medical emergency.

WARNINGS AND PRECAUTIONS

BUPHENYL should not be administered to patients with known hypersensitivity to sodium phenylbutyrate or any component of this preparation.

Use caution with administering BUPHENYL to patients with:
- Congestive heart failure or severe renal insufficiency, and in clinical states in which there is sodium retention with edema.
- Hepatic or renal insufficiency or inborn errors of beta oxidation.
Probenecid may affect renal excretion of the conjugated product of BUPHENYL as well as its metabolite.
Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels.
There have been published reports of hyperammonemia being induced by haloperidol and by valproic acid.

ADVERSE REACTIONS

The most common adverse reactions (≥3%) reported in BUPHENYL clinical trials were decreased appetite, body odor, bad taste or taste aversion.
In female patients, amenorrhea/menstrual dysfunction (irregular menstrual cycles) occurred in 23% of the menstruating patients.
Neurotoxicity was reported in cancer patients receiving intravenous phenylacetate. Manifestations were predominately somnolence, fatigue, and lightheadedness; with less frequent headache, dysgeusia, hypoacusis, disorientation, impaired memory, and exacerbation of a pre-existing neuropathy.
Laboratory adverse events occurring in >2% of UCD patients by body system were:
- Metabolic: acidosis, alkalosis, hyperchloremia, and hypophosphatemia
- Nutritional: hypoalbuminemia and decreased total protein
- Hepatic: increased alkaline phosphatase and increased liver transaminases
- Hematologic: anemia, leukopenia, leukocytosis, and thrombocytopenia

USE IN SPECIFIC POPULATIONS

Pregnancy: BUPHENYL should be used with caution in patients who are pregnant or planning to become pregnant. Animal reproduction studies have not been conducted with BUPHENYL. It is not known whether BUPHENYL can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
Lactation: breastfeeding is not recommended during treatment with BUPHENYL. There are no data on the presence of BUPHENYL in human milk.

Please see Full Prescribing Information.